Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Onset of Ixekizumab in Psoriasis
NCT02387801Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2015
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixekizumab in plaque psoriasis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score. Started Apr 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02387801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387801.